Weight Loss Drugs Could Prop Up Manufacturing Construction -- Market Talk

Dow Jones

2025/07/18

1455 ET - For manufacturing construction companies, such as Jacob Solutions and Fluor, EV plants are out and GPL-1 factories are in. Multibillion EV and semiconductor projects are close to being completed, but investment by pharmaceutical companies, boosted by huge demand for weight loss drugs, could fill the upcoming revenue void for the construction industry, say UBS analysts in a research note. The analysts estimate $280 billion committed by pharmaceutical companies to manufacturing construction in the next four to five years, which would add 0.5% to 1% growth in both 2026 and 2027 to non-residential construction spending. The investments will help pharma companies avoid tariffs while ramping up production of weight loss drugs. (nicholas.miller@wsj.com)

(END) Dow Jones Newswires

July 17, 2025 14:55 ET (18:55 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2552439643"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2552439643\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2552439643?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-18 02:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2552439643","market":"hk","top_or_hot":-1,"title":"Weight Loss Drugs Could Prop Up Manufacturing Construction -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1455 ET - For manufacturing construction companies, such as Jacob Solutions and <a href=\"https://laohu8.com/S/FLR\">Fluor</a>, EV plants are out and GPL-1 factories are in. Multibillion EV and semiconductor projects are close to being completed, but investment by pharmaceutical companies, boosted by huge demand for weight loss drugs, could fill the upcoming revenue void for the construction industry, say UBS analysts in a research note. The analysts estimate $280 billion committed by pharmaceutical companies to manufacturing construction in the next four to five years, which would add 0.5% to 1% growth in both 2026 and 2027 to non-residential construction spending. The investments will help pharma companies avoid tariffs while ramping up production of weight loss drugs. (nicholas.miller@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2025 14:55 ET (18:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Weight Loss Drugs Could Prop Up Manufacturing Construction -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWeight Loss Drugs Could Prop Up Manufacturing Construction -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-18 02:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1455 ET - For manufacturing construction companies, such as Jacob Solutions and <a href=\"https://laohu8.com/S/FLR\">Fluor</a>, EV plants are out and GPL-1 factories are in. Multibillion EV and semiconductor projects are close to being completed, but investment by pharmaceutical companies, boosted by huge demand for weight loss drugs, could fill the upcoming revenue void for the construction industry, say UBS analysts in a research note. The analysts estimate $280 billion committed by pharmaceutical companies to manufacturing construction in the next four to five years, which would add 0.5% to 1% growth in both 2026 and 2027 to non-residential construction spending. The investments will help pharma companies avoid tariffs while ramping up production of weight loss drugs. (nicholas.miller@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 17, 2025 14:55 ET (18:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FLR","symbol_name":"福陆","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2552439643","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2552439643","pubTimestamp":1752778500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1455 ET - For manufacturing construction companies, such as Jacob Solutions and Fluor, EV plants are out and GPL-1 factories are in. Multibillion EV and semiconductor projects are close to being completed, but investment by pharmaceutical companies, boosted by huge demand for weight loss drugs, could fill the upcoming revenue void for the construction industry, say UBS analysts in a research note. The analysts estimate $280 billion committed by pharmaceutical companies to manufacturing construction in the next four to five years, which would add 0.5% to 1% growth in both 2026 and 2027 to non-residential construction spending. The investments will help pharma companies avoid tariffs while ramping up production of weight loss drugs. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FLR":"福陆","BK4588":"碎股","J":"雅各布工程","BK4123":"调查和咨询服务","BK4585":"ETF&股票定投概念","BK4129":"建筑与工程"},"translate_title":"减肥药可以支撑制造业建设——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"J":0.9,"FLR":0.9},"content_text":"1455 ET - For manufacturing construction companies, such as Jacob Solutions and Fluor, EV plants are out and GPL-1 factories are in. Multibillion EV and semiconductor projects are close to being completed, but investment by pharmaceutical companies, boosted by huge demand for weight loss drugs, could fill the upcoming revenue void for the construction industry, say UBS analysts in a research note. The analysts estimate $280 billion committed by pharmaceutical companies to manufacturing construction in the next four to five years, which would add 0.5% to 1% growth in both 2026 and 2027 to non-residential construction spending. The investments will help pharma companies avoid tariffs while ramping up production of weight loss drugs. (nicholas.miller@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 17, 2025 14:55 ET (18:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}